Glaucoma laser treatment ready to go to trial

Article

Israeli firm IOPtima has completed development of its novel laser-based therapy for the treatment of glaucoma, OT134.

Israeli firm IOPtima has completed development of its novel laser-based therapy for the treatment of glaucoma, OT134.

The second-generation OT134 system is based on the company's smart laser-based technology known as LNPDS (CO2 Laser Non-Penetrating Deep Sclerectomy) that has already undergone successful testing on 23 patients in clinical trials. The OT134 upgrades have been designed to offer improved efficacy and ergonomics.

IOPtima plans to initiate a multinational, long-term, human clinical trial later this year.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.